Engineering protein glycosylation in CHO cells to be highly similar to murine host cells

Since 2015 more than 34 biosimilars have been approved by the FDA. This new era of biosimilar competition has stimulated renewed technology development focused on therapeutic protein or biologic manufacturing. One challenge in biosimilar development is the genetic differences in the host cell lines...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Shivani, Shah, Bhavana, Fung, Coral Shek, Chan, Pik Kay, Wakefield, Devin L., Kuhns, Scott, Goudar, Chetan T., Piret, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978007/
https://www.ncbi.nlm.nih.gov/pubmed/36873370
http://dx.doi.org/10.3389/fbioe.2023.1113994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978007/
https://www.ncbi.nlm.nih.gov/pubmed/36873370
http://dx.doi.org/10.3389/fbioe.2023.1113994

Ejemplares similares